Natera, Inc.(NTRA) - Stock detail

Natera, Inc.

US
NTRA
Natera, Inc.(Listing date: 07/02/2015)

Natera, Inc. was incorporated in Delaware in January 2007. The company is a diagnostic company with proprietary molecular and bioinformatics technologies that it is applying to transform disease management worldwide. The company's cell-free DNA (cfDNA) technology combines novel molecular analytical methods that can reliably measure many informative regions across the entire genome from samples as small as a single cell, as well as statistical algorithms that incorporate data provided by the broader scientific community to identify genetic variations covering a wide range of serious diseases with high precision and high coverage. The company's goal is to make personalized genetic testing and diagnosis part of the standard of care for protecting health and inform earlier and more targeted interventions to help achieve longer, healthier lives.

AI Rating

Rating methodology
Latest close (chg%)219.82+2.20%
Buy price
195.00
Target price195.00
Sell price206.00
P/E TTM-103.56
P/E-168.14
Confidence80%
Risk score70/100
AI Summary
The committee finds the conservative argument most compelling. The stock is at extreme overbought levels with a high P/S ratio of 13.61 and widening net losses, indicating unsustainable valuation. Technicals show a low ADX (weak trend) and overbought oscillators, while sentiment analysis reveals 85.94% of traders are in profit, creating imminent profit-taking pressure. The $195 target represents a necessary valuation reset to a more reasonable P/S multiple (~10x) and aligns with technical support near the April low.

Alpha Score

0-10
  • Trend（Score 4/10）

    Technical analysis shows a short-term bullish breakout with strong momentum but multiple overbought signals suggest the rally may be overextended and due for a pullback.

  • Valuation（Score 3/10）

    Valuation metrics reflect a premium pricing for growth despite current losses, with a high PS ratio of 13.61 and extremely high PB ratio of 25.42. The stock is not undervalued by traditional fundamental metrics and is priced for perfection in terms of future growth expectations.

  • Financial strength（Score 7/10）
    The company's financial health appears robust in terms of liquidity with strong current and quick ratios, but strained by profitability with moderate leverage. Strong liquidity suggests no immediate cash crunch, supporting ongoing operations and growth initiatives.
  • Profitability（Score 4/10）
    Natera exhibits a high-growth yet unprofitable profile with exceptional revenue growth of 35.90% year-over-year and improving gross margins, but persistent net losses and negative return metrics indicate it is currently destroying shareholder value from an accounting profitability standpoint.
  • Sentiment（Score 8/10）
    The news analysis presents an overwhelmingly positive and unified bullish narrative for Natera (NTRA), driven by high-profile investor conviction, analyst validation, fundamental catalysts like a legal win and strong product adoption, and a clear path to profitability.
Latest price
$219.82+2.20%
Market cap31.39B
P/E TTM-103.56
P/E-168.14
Volume2.52M
Turnover546.03M